NCT01089101 2026-03-18
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
10 trialsNCT03919071 2026-03-18
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06860594 2026-03-18
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04197934 2026-02-12
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Mayo Clinic
Phase 1 Active not recruiting
NCT07301268 2026-02-03
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Phase 2 Suspended
NCT07089641 2025-11-24
ERAS801-SARG
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT05789394 2025-10-27
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Mayo Clinic
Phase 1 Recruiting
NCT04729959 2025-10-20
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03180502 2025-07-11
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
Phase 2 Active not recruiting
NCT06815029 2025-06-26
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
Phase 1 Recruiting